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Abstract
Background: Epidemiological evidence suggests that fibrinogen and CRP are associated with coronary heart
disease risk. High CRP in Indigenous Australians has been reported in previous studies including our ‘Diabetes and
Related diseases in Urban Indigenous population in Darwin region’ (DRUID) Study. We studied levels of fibrinogen
and its cross-sectional relationship with traditional and non-traditional cardiovascular risk factors in an urban
Indigenous Australian cohort.
Methods: Fibrinogen data were available from 287 males and 628 females (aged ≥ 15 years) from the DRUID
study. Analysis was performed for associations with the following risk factors: diabetes, HbA1c, age, BMI, waist
circumference, waist-hip ratio, total cholesterol, triglyceride, HDL cholesterol, C-reactive protein, homocysteine,
blood pressure, heart rate, urine ACR, smoking status, alcohol abstinence.
Results: Fibrinogen generally increased with age in both genders; levels by age group were higher than those
previously reported in other populations, including Native Americans. Fibrinogen was higher in those with than
without diabetes (4.24 vs 3.56 g/L, p < 0.001). After adjusting for age and sex, the following were significantly
associated with fibrinogen: BMI, waist, waist-hip ratio, systolic blood pressure, heart rate, fasting triglycerides, HDL
cholesterol, HbA1c, CRP, ACR and alcohol abstinence. On multivariate regression (age and sex-adjusted) CRP and
HbA1c were significant independent predictors of fibrinogen, explaining 27% of its variance; CRP alone explained
25% of fibrinogen variance. On factor analysis, both CRP and fibrinogen clustered with obesity in women (this
factor explained 20% of variance); but in men, CRP clustered with obesity (factor explained 18% of variance) whilst
fibrinogen clustered with HbA1c and urine ACR (factor explained 13% of variance).
Conclusions: Fibrinogen is associated with traditional and non-traditional cardiovascular risk factors in this urban
Indigenous cohort and may be a useful biomarker of CVD in this high-risk population. The apparent different
associations of fibrinogen with cardiovascular disease risk markers in men and women should be explored further.
Background
Indigenous Australians have rates of cardiovascular dis-
ease (CVD) mortality some 7-10 times higher than non-
Indigenous Australians at ages 25-64 years and a life
expectancy that is 15-20 years shorter [1]. Fibrinogen is
an inflammatory biomarker that has been independently
associated with CVD outcomes (both coronary heart dis-
ease and stroke) [2]. Fibrinogen plays a key role in
thrombus formation, platelet aggregation and is a major
contributor to plasma viscosity. It is also an acute phase
reactant, increased in inflammatory states, and is closely
associated with C-reactive protein [3]. As expected, fibri-
nogen is associated with traditional cardiovascular risk
factors such as age, cigarette smoking, lipids, body mass
index, diabetes, and blood pressure in many population
groups (including North American whites, Japanese and
Native Americans) [3-6]. Fibrinogen has recently been
associated with impaired myocardial systolic function [7]
and abnormalities of circadian blood pressure variability
and endothelial function in obese participants [8]. Higher
fibrinogen has also been associated with alcohol absti-
nence and socio-economic disadvantage [3,9].
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Indigenous Australians (Aborigines and Torres Strait
Islanders) in remote areas have been reported to have high
fibrinogen levels compared to other population groups;
fibrinogen increased with age and was associated with tra-
ditional cardiovascular risk factors but these factors only
explained 12% of the variance in fibrinogen on multiple
regression analysis [10]. Similarly, fibrinogen levels have
been reported to be high in other Indigenous populations
internationally, including Canadian Aboriginals and Native
Americans [11,12]. In the Strong Heart Study of Native
Americans, fibrinogen levels predicted cardiovascular
events independent of traditional risk factors in a popula-
tion-based sample of adults without clinical evidence of
coronary heart disease at baseline [6]. The addition of
fibrinogen (along with urine albumin-creatinine ratio,
ACR) to standard clinical and laboratory risk factors
improved discrimination of a multimarker model for
prediction of CVD events [12].
Most studies of Indigenous Australians concern those
living in rural and remote regions. Less is known about
health patterns in urban areas, where the majority of
Indigenous Australians live [13]. The Darwin Region
Urban Indigenous Diabetes (DRUID) Study was designed
to address this knowledge gap. The aims of this paper are
to evaluate levels of fibrinogen and its association with
traditional and novel cardiovascular risk markers in an
urban Indigenous Australian cohort, a population with
high rates of diabetes, obesity and premature CVD.
Methods
Participants
The DRUID Study was a cross-sectional study of
approximately 1,000 urban Indigenous people from Dar-
win, Australia, undertaken from September 2003 to
March 2005. Darwin, the capital of the Northern Terri-
tory, is the northern-most capital city in Australia and is
situated on the Timor Sea, thus is relatively close to
Asia. In 2001, Indigenous people represented approxi-
mately 2% of the Australian population, 29% of the
Northern Territory population, and 10% of the Darwin
Region population [13,14]. DRUID participants met the
following eligibility criteria: self-identified as Aboriginal
and/or Torres Strait Islander; aged ≥ 15 years; had
resided within a specified geographical region around
Darwin for at least six months; and living in a private
dwelling. All participants underwent a 75 gm oral glu-
cose tolerance test (OGTT) unless pregnant or on medi-
cations for diabetes. Blood samples were taken fasting
and at 2 hours (for those who had OGTT). The DRUID
study was a volunteer cohort including approximately
14% of the estimated target population, and therefore
not necessarily representative of the target population.
The population, methods and response rates have been
previously described [15].
Anthropometry, blood pressure, biochemistry and
health behaviours
Measures were performed as described previously
[15,16]. In brief: body weight was recorded to the near-
est 0.1 kilogram using a digital scale weighing up to
200 kg (Model 767, Seca Deutschland, Hamburg,
Germany); height was recorded to the nearest 0.1 cm
using a portable stadiometer (Model PE87, Mentone
Educational Centre, Moorabbin, Victoria, Australia);
waist and hip circumferences were measured to the
nearest 0.1 cm using a 2-metre non-stretch fiberglass
tape; sitting blood pressure and heart rate were mea-
sured using a Welch Allyn Spot Vital Signs monitor
(Welch Allyn Medical products, Skaneateles Falls, USA).
Smoking status and alcohol abstinence were based on
self-report. The following parameters were measured in
fasting blood as previously described [15]: HbA1c
(EDTA whole blood); glucose, insulin, homocysteine
(fluoride/EDTA plasma); cholesterol, triglycerides, HDL
cholesterol, hs-CRP (serum). Albumin and creatinine
concentrations were measured in urine as previously
reported [15]. Diabetes diagnosis was based on OGTT,
using the 1999 WHO diabetes classification [17].
Fibrinogen was measured by Clauss method on IL
Futura Plus by the Clinical Trials Laboratory (Flinders
Medical Centre, Bedford Park, SA) [15]. A total of 1,004
participants provided at least 1 measurement in DRUID;
n = 89 were excluded from this analysis as they did not
have a blood sample for assessment of fibrinogen level,
thus n = 915 were included in this analysis.
Statistical Analysis
Data analysis was performed using STATA v10.0 (Stata
Corporation, TX, USA). Variables with distributions sig-
nificantly different from normal were log transformed
(natural log). Data are presented as mean (standard
deviation) or geometric mean (95% confidence interval).
Participants with a self-reported history of coronary
artery disease were not excluded for analysis of fibrino-
gen. To determine associations between risk factors and
fibrinogen, bivariate associations were assessed using lin-
ear regression. Multiple regression models with fibrino-
gen as the dependent variable were then calculated
using backwards stepwise regression models; all estab-
lished risk factors and other variables identified as sig-
nificant in bivariate analyses were considered for
inclusion. Goodness of fit was assessed using likelihood-
ratio tests to compare nested models; a significance level
of p < 0.05 was used. Associations between risk factors
and fibrinogen were also assessed by grouping partici-
pants into tertiles of fibrinogen and then stratifying by
gender. Factor analysis was used to examine clustering
of risk factors. Factor analysis used principal compo-
nents methods to reduce the information in many
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measured variables into a smaller set of “factors"; com-
munalities were assumed to be one. Kaiser’s criterion
(eigen values > 1) was used to determine the number of
factors that best described the underlying relationship
among variables. The extracted factors were rotated
using varimax rotation. Significant correlations were
considered for variables loading ≥ 0.40.
Ethical Approval
Ethics approval was given by the combined Human
Research Ethics Committee of Northern Territory
Department of Health and Community Services and
Menzies School of Health Research, Darwin. This
included review by both the Aboriginal Sub-Committee
and the main committee.
Results
Characteristics of participants are presented in Table 1.
Fibrinogen levels for n = 915 DRUID participants gener-
ally increased with age in both genders (Figure 1). Mean
(geometric) fibrinogen was 3.75 g/L for women (mean
age 37 years) and 3.52 g/L for men (mean age 35 years).
Across tertiles of fibrinogen, there was an increase in
cardiovascular risk markers with the exception of cigar-
ette smoking in women (Table 2). Participants with dia-
betes had higher mean fibrinogen than participants
without diabetes (4.24 vs 3.56 g/L, p < 0.001) and the
difference remained significant after adjusting for age
and gender.
Bivariate associations (correlation coefficient, r) with
fibrinogen were as follows (units are as shown in Table 2):
age (0.18), waist circumference (0.29), waist-hip ratio
(WHR, 0.17), body mass index (BMI, 0.30), systolic blood
pressure (0.14), diastolic blood pressure (0.15), heart rate
(0.16), HbA1c (0.26), total cholesterol (0.07), HDL choles-
terol (-0.14), triglycerides (0.12), CRP (0.46) and urine
ACR (0.17) where p < 0.001 for all except gender (p =
0.002) and total cholesterol (p = 0.008). Beta coefficients
for associations with categorical variables were: female
gender (0.28, p < 0.001) and alcohol abstinence (0.27, p =
0.003). Associations remained significant after adjusting
for age and gender with the exception of total cholesterol.
The relationship between WHR and fibrinogen was signif-
icantly stronger for men [beta coefficient (95%CI) = 4.08
(2.58-5.57)] than for women [2.07(1.06-3.07)] (p for inter-
action term = 0.038). By contrast, the relationship between
BMI and fibrinogen was stronger for women [beta coeffi-
cient (95%CI) = 0.051(0.039-0.064)] than for men [0.048
(0.026-0.070)], although this was not statistically signifi-
cant (p for interaction term = 0.79). There was no signifi-
cant association between fibrinogen and being a current
cigarette smoker (compared to former or never smoked
combined).
Factors independently associated with fibrinogen on
multiple regression (adjusted for age and gender) were
CRP and HbA1c (Table 3). CRP alone was associated
with 25.5% of the variance in fibrinogen, with an addi-
tional 1% from the combination of age, gender and
HbA1c. There were no significant interactions between
gender and HbA1c or CRP. Results were similar if the
model was stratified by gender (data not shown). If par-
ticipants with diabetes were excluded, CRP was the only
variable independently associated with fibrinogen
(adjusted for age and gender).
Results of factor analysis for fibrinogen are presented
in Table 4, stratified by gender. In women, CRP and
fibrinogen both clustered with the first factor, labelled
“obesity"; whereas in men, CRP clustered with obesity
whilst fibrinogen (with CRP) clustered with HbA1c/
ACR, labelled “metabolic”.
Discussion
We have reported that amongst this high risk popula-
tion (urban Indigenous Australians): levels of fibrinogen
are similar to those previously reported for remote
Aboriginal Australians but higher than those reported
for Native Americans or Canadian Aboriginals; CRP was
strongly associated with fibrinogen (in agreement with
other studies [3,18,19]); and factor analysis revealed gen-
der differences for clustering of fibrinogen and CRP
with obesity and related metabolic factors.
Mean fibrinogen levels in The Strong Heart Study for
those with diabetes compared to those without were:
3.49 vs 3.32 (mean age 59.5 vs 58.9 years) [12]; in Cana-
dian Aboriginals of the SHARE study: mean fibrinogen
was 3.69 g/L (mean age 53.1 years). The mean fibrino-
gen of the DRUID cohort was higher than/similar to
those above at 3.68 g/L but in a strikingly younger
group (mean age 36 years), although the above studies
may not be directly comparable due to different
Table 1 Participant Characteristics, data are n (%)
Female (n = 628)
n (%)
Male (n = 287)
n (%)
Age Group
15-24 years 146 (23%) 86 (30%)
25-34 years 135 (21%) 58 (20%)
35-44 years 148 (24%) 66 (23%)
45-54 years 120 (19%) 50 (18%)
55-64 years 55 (9%) 21 (7%)
65+ years 24 (4%) 6 (2%)
Diabetes 121 (21%) 41 (16%)
Cigarette Smoker 250 (44%) 115 (43%)
BMI Category
BMI < 25 212 (35%) 98 (35%)
BMI 25-29 164 (27%) 102 (36%)
BMI ≥ 30 224 (38%) 83 (29%)
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Figure 1 Fibrinogen by age group and gender.
Table 2 Cardiovascular risk markers across tertiles of fibrinogen (g/L) for urban Indigenous Australian adults in the
DRUID Study.
Fibrinogen Tertiles
Females
Fibrinogen Tertiles
Males
Low*
(n = 201)
Mid*
(n = 210)
High*
(n = 217)
Low*
(n = 119)
Mid*
(n = 102)
High*
(n = 66)
Age (years) 35.0 ± 13.8 36.9 ± 15.3 40.1 ± 14.3 30.4 ± 13.2 35.3 ± 13.8 41.6 ± 13.6
BMI (kg/m2) 26.0 ± 7.1 28.1 ± 6.8 31.8 ± 7.9 25.6 ± 5.3 28.3 ± 5.5 29.3 ± 6.1
Waist (cm) 88.3 ± 17.2 91.8 ± 16.3 100.9 ± 16.4 90.6 ± 14.1 98.3 ± 13.6 102.1 ± 16.1
Systolic BP (mmHg) 113 ± 16 114 ± 16 118 + 16 117 ± 14 122 ± 14 126 ± 17
Diastolic BP
(mmHg)
71 ± 10 72 ± 10 75 ± 9 72 ± 11 75 ± 11 78 ± 10
Heart Rate (beats/min) 73 ± 11 74 ± 10 77 ± 12 70 ± 13 72 ± 12 77 ± 13
Diabetes (%) 12.2 19.0 31.0 8.2 13.5 32.8
Smoker (%) 48.4 41.5 42.3 39.8 43.8 45.9
Fibrinogen (g/L) 2.5 (2.4-2.6) 3.9 (3.88-3.96) 5.3 (5.2-5.4) 2.6 (2.5-2.8) 3.8 (3.76-3.89) 5.2 (5.1-5.4)
Total cholesterol (mmol/L) 4.8 (4.6 - 4.9) 4.9 (4.8 - 5.0) 4.9 (4.7 - 5.0) 4.8 (4.6 -5.0) 5.0 (4.8 - 5.2) 5.3 (5.1 - 5.6)
LDL Cholesterol (mmol/L) 2.8 (2.7 - 3.0) 2.9 (2.8 - 3.1) 3.0 (2.8 - 3.1) 2.9 (2.7 - 3.1) 3.0 (2.8 - 3.2) 3.3 (3.0 - 3.5)
HDL cholesterol (mmol/L) 1.2 (1.17 - 1.3) 1.15 (1.11- 1.2) 1.07(1.03- 1.1) 1.1 (1.0 - 1.2) 1.0 (0.9 - 1.0) 1.0 (0.9 - 1.0)
Triglycerides
(mmol/L)
1.2 (1.1 - 1.3) 1.4 (1.3 - 1.5) 1.5 (1.4 - 1.6) 1.4 (1.3 - 1.6) 1.9 (1.6 - 2.1) 2.1 (1.8 - 2.5)
HbA1c (%) 5.3 (5.2 - 5.4) 5.6 (5.4 - 5.7) 5.9 (5.8 - 6.1) 5.2 (5.1 - 5.3) 5.6 (5.4 - 5.8) 6.2 (5.8 - 6.5)
CRP (mg/L) 1.9(1.6 - 2.3) 3.2 (2.7 - 3.7) 8.0 (7.0 - 9.2) 1.2 (1.0 - 1.4) 2.5 (2.1 - 3.0) 7.0 (5.7 - 8.6)
Homocysteine (μmol/L) 8.8 (8.4-9.2) 8.8 (8.3-9.2) 9.3 (8.9-9.8) 9.6 (9.1-10.2) 11.7
(10.7-12.7)
11.4
(10.3-12.6)
ACR (mg/mmol) 0.8 (0.7 - 0.9) 1.0 (0.8 - 1.3) 1.2 (0.9 - 1.5) 0.5 (0.4 - 0.6) 0.6 (0.5 - 0.8) 1.6 (0.9 -2.7)
Values are mean ± standard deviation or geometric mean (95% confidence interval) for continuous variables or percent for dichotomous parameters.
BMI, body mass index; BP, blood pressure; CRP, c-reactive protein; ACR, urine albumin-creatinine ratio
*Fibrinogen Tertiles: Low, 0.9-3.3; Mid, 3.4-4.4; High, 4.5-9.7 g/L
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methodologies used. Consistent with other reports
[12,20], fibrinogen was higher in DRUID participants
with diabetes compared to those without diabetes.
The Strong Heart Study of Native Americans reported
that fibrinogen was a useful biomarker in significantly
improving CVD risk prediction by multimarker models,
whereas CRP was not so useful [12]. The authors postu-
late that there are differences in the prognostic proper-
ties of biomarkers when adiposity and insulin resistance
are widespread in a population. Indigenous Australians
are a similar high risk population to that of The Strong
Heart Study with regard to high rates of insulin resis-
tance, diabetes, obesity and premature CVD. Our find-
ing of differences in genders between the clustering of
fibrinogen and CRP on factor analysis suggests that
fibrinogen is not as strongly associated with adiposity as
is CRP, particularly in men, and could therefore be a
more useful marker of CVD risk than CRP, as reported
for Native Americans above [12]. We have previously
reported a gender-differential for CRP: a stronger asso-
ciation with adiposity in remote Aboriginal women than
men [21].
Our findings of a gender-differential on factor analysis
of markers of inflammation such as CRP and fibrinogen
are consistent with those of Hanley et al [22]; in that
study of nondiabetic participants, adiposity measures
(BMI and waist) loaded with inflammatory markers
(CRP and fibrinogen) in women but with metabolic vari-
ables (insulin sensitivity) in men. However, in contrast
to our findings, CRP and fibrinogen loaded together in
both genders. Both that study and another previous
report of factor analysis involving fibrinogen [23]
reported broadly similar factors to that of our report:
obesity/body mass, glucose/insulin/metabolic, inflamma-
tion, lipids and blood pressure.
It is interesting to note that CRP was strongly asso-
ciated with fibrinogen on multiple regression in the cur-
rent study, alone explaining 25.5% of the variance, when
the full model explained 26.5% of variance in fibrinogen.
The Fibrinogen Studies Collaboration reported that CRP
explained 10% of the variance of fibrinogen in a large
Table 3 Multiple linear regression analysis of fibrinogen
Coeff. Std. Err. p 95% Conf Interval
Age (yrs) -0.001 0.003 0.538 -0.007, 0.004
Female 0.056 0.079 0.477 -0.098, 0.210
CRP* 0.467 0.031 < 0.001 0.406, 0.529
HbA1c .0956 0.030 0.002 0.037, 0.155
Model r2 = 26.5%, n = 900
*log transformed
Table 4 Factor analysis of fibrinogen by gender*
Factor 1: ‘Obesity’ Factor 2: ‘Blood Pressure’ Factor 3: ‘Metabolic’ Factor 4: ‘Dyslipidaemia’
F M F M F M F M
Age 0.21 0.13 0.64 0.45 0.17 0.28 0.13 0.46
Fibrinogen 0.52 0.27 0.03 0.00 0.19 0.78 0.12 0.04
CRP 0.75 0.47 0.20 0.19 0.12 0.65 0.20 0.14
Homocyst -0.02 -0.15 0.17 0.30 0.22 0.45 0.48 -0.18
Insulin 0.66 0.70 -0.10 0.02 0.34 0.18 -0.07 0.13
HDL -0.41 -0.45 -0.02 0.14 -0.30 0.00 -0.39 -0.67
Trig 0.17 0.21 0.29 0.18 0.22 0.06 0.53 0.73
HbA1c 0.27 -0.05 0.34 0.24 0.46 0.52 0.25 0.49
BMI 0.90 0.91 0.15 0.16 -0.09 0.04 -0.11 0.09
Waist 0.88 0.88 0.25 0.24 0.01 0.14 0.01 0.13
SBP 0.17 0.20 0.89 0.89 0.05 0.05 -0.04 0.04
DBP 0.15 0.19 0.88 0.90 -0.05 0.10 0.01 0.06
ACR -0.01 -0.25 0.24 0.45 0.50 0.45 0.39 0.32
Smoker -0.12 -0.26 -0.16 0.08 -0.31 0.16 0.74 0.17
Heart rate 0.04 0.10 0.12 0.41 0.10 0.41 0.12 -0.18
Alcohol -0.01 0.07 0.04 0.15 -0.83 -0.06 0.15 0.03
% variance explained 20 18 15 16 10 13 10 11
Significant correlations were considered for variables loading ≥ 0.40, highlighted in bold
* Five factors with eigen value > 1 were identified in both men and women, but the last of these was not readily interpretable and has not been considered
further.
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meta-analysis of 154,211 adults; cohort, age and sex
explained one third of the variance and traditional CVD
risks explained 7% of the variance [3]. This is consistent
with the report of remote Australian Aborigines and
Torres Strait Islanders, where traditional cardiovascular
risks explained only 12% of the variance in fibrinogen
(CRP was not assessed in that study) [10]. Although
CRP and fibrinogen were closely associated, the marked
difference between genders that has been reported for
CRP was not apparent for fibrinogen.
Consistent with previous studies of remote Australian
Aborigines, cigarette smoking was not significantly asso-
ciated with fibrinogen in the DRUID cohort [10]. This is
not consistent with reports from other populations [3],
but could be explained by the lack of quantitative data
on cigarette smoking in the current study or the high
rates of cigarette smoking amongst Indigenous Austra-
lians (44% in DRUID) so that it is not a useful
discriminator.
Our study has several limitations: the DRUID study is
cross-sectional and composed of volunteers (two-thirds
female); confounding by unmeasured factors is possible.
Despite such limitations, these data represent the best
currently available data for an urban Indigenous popula-
tion in Australia. This is particularly important given
that 73% of the total Indigenous population of Australia
live in urban centres [13]. There may be similar knowl-
edge gaps relating to other Indigenous populations
internationally due to mismatches between where
research is undertaken and where people actually live.
Conclusions
Fibrinogen levels are elevated in this high-risk urban
Indigenous cohort, are associated with traditional and
non-traditional cardiovascular risk factors and, although
closely related to CRP, may not be influenced as much
by obesity as is CRP (in men). We therefore propose
that fibrinogen may be a useful biomarker of CVD risk
in this high-risk population and await results of longitu-
dinal follow-up of this cohort and other longitudinal
studies.
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